Benedict Financial Advisors Inc. decreased its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.9% in the 4th quarter, HoldingsChannel reports. The firm owned 19,764 shares of the medical instruments supplier’s stock after selling 177 shares during the period. Becton Dickinson and comprises 2.2% of Benedict Financial Advisors Inc.’s holdings, making the stock its 9th biggest position. Benedict Financial Advisors Inc.’s holdings in Becton Dickinson and were worth $4,453,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after buying an additional 283,433 shares in the last quarter. Vanguard Group Inc raised its position in shares of Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after buying an additional 283,433 shares in the last quarter. BlackRock Inc. raised its position in shares of Becton Dickinson and by 1.3% in the 3rd quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock valued at $4,966,582,000 after buying an additional 253,041 shares in the last quarter. FMR LLC raised its position in shares of Becton Dickinson and by 8.0% in the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after buying an additional 1,286,579 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Becton Dickinson and by 0.8% in the 3rd quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock valued at $930,491,000 after buying an additional 27,188 shares in the last quarter. Institutional investors and hedge funds own 83.82% of the company’s stock.

In other Becton Dickinson and news, EVP James W. Borzi sold 5,887 shares of the business’s stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the sale, the executive vice president now directly owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles R. Bodner sold 2,080 shares of the business’s stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $245.83, for a total transaction of $511,326.40. Following the sale, the senior vice president now directly owns 4,497 shares in the company, valued at $1,105,497.51. The disclosure for this sale can be found here. Insiders have sold a total of 81,795 shares of company stock worth $19,571,318 over the last three months. Insiders own 0.12% of the company’s stock.

Shares of Becton Dickinson and stock opened at $247.42 on Friday. The company has a market cap of $66.37 billion, a P/E ratio of 22.47, a P/E/G ratio of 1.76 and a beta of 1.21. The company has a debt-to-equity ratio of 0.90, a quick ratio of 0.69 and a current ratio of 1.03. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The firm had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the firm posted $2.40 EPS. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. Equities research analysts forecast that Becton Dickinson and Co will post 12.11 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s payout ratio is 27.97%.

Several brokerages have recently commented on BDX. UBS Group began coverage on shares of Becton Dickinson and in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 target price for the company. Deutsche Bank began coverage on shares of Becton Dickinson and in a research report on Thursday, December 6th. They issued a “buy” rating and a $280.00 target price for the company. Wells Fargo & Co dropped their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, November 7th. Piper Jaffray Companies dropped their target price on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, November 6th. Finally, Barclays started coverage on shares of Becton Dickinson and in a research report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 target price for the company. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $251.17.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2019/02/02/becton-dickinson-and-co-bdx-shares-sold-by-benedict-financial-advisors-inc.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Initial Public Offering (IPO)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.